Metraipolis › archive › dc_e9150bdd993c

Repositioned donafenib versus standard regorafenib for second-line HCC treatment: A matched cohort study — Europe PMC PMID:42071878

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42071878
DOI
10.1097/md.0000000000048470
License (as archived)
solo-consultazione
Archived
2026-11-03T14:05:06.976Z
SHA-256 of the archived text
ff4a85dcb19809c27e78eb66655a970b1a111477ec60983cdd3074f9e9133a6d
Stable URL of this page
https://metraipolis.com/documento/dc_e9150bdd993c

How to cite

Repositioned donafenib versus standard regorafenib for second-line HCC treatment: A matched cohort study — Europe PMC PMID:42071878 — Europe PMC (en), https://europepmc.org/article/MED/42071878 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e9150bdd993c (Metraipolis archive dc_e9150bdd993c, sha256 ff4a85dcb19809c27e78eb66655a970b1a111477ec60983cdd3074f9e9133a6d)
BibTeX
@misc{dce9150bdd993c,
  title = {Repositioned donafenib versus standard regorafenib for second-line HCC treatment: A matched cohort study — Europe PMC PMID:42071878},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42071878},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e9150bdd993c; sha256 ff4a85dcb19809c27e78eb66655a970b1a111477ec60983cdd3074f9e9133a6d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42071878. Agents can read the archived copy with the MCP tool read_document.